ALDEA Pharmaceuticals

About:

ALDEA Pharmaceuticals develops small-molecule modulators of the ALDH family for the treatment of toxic aldehyde-related diseases.

Website: http://www.aldeapharmaceuticals.com/

Top Investors: Canaan Partners, Correlation Ventures, WuXi AppTec, RMI Partners

Description:

ALDEA Pharmaceuticals is developing small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) family, to treat toxic aldehyde-related diseases. This proprietary technology represents new product opportunities to address novel targets across multiple therapeutic areas. For example, an ALDH activator compound enhances the detoxification of acetaldehyde in the alcohol metabolism pathway, to treat acute symptoms and to reduce long-term tissue damage and cancer risk. The company was founded in 2011 and headquartered in Redwood City, California.

Total Funding Amount:

$42M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Redwood City, California, United States

Founded Date:

2011-01-01

Contact Email:

info(AT)aldeapharma.com

Founders:

Che-Hong Chen, Daria Mochly Rosen, Wenjin Yang

Number of Employees:

11-50

Last Funding Date:

2014-08-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai